Why the study?
Do NOACs reduce stroke/SEE and major bleeding compared to warfarin in patients with atrial fibrillation across the spectrum of body mass index and body weight?
Do NOACs reduce stroke/SEE and major bleeding compared to warfarin in patients with atrial fibrillation across the spectrum of body mass index and body weight?
Answers are grounded in this paper and cite their sources.
NOACs maintain stroke prevention efficacy versus warfarin across BMI; extends evidence on attenuated bleeding reduction at higher weights.
The treatment effect of NOACs versus warfarin in atrial fibrillation is generally consistent for stroke/SEE across the spectrum of BMI and BW, whereas the reduction in major bleeding is attenuated in those with higher BMI or BW. Death and the net clinical outcome are overall reduced with NOACs over warfarin, although there remain uncertainties for these outcomes at a very high BMI and BW.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: